Clinical trials: Advanced Cirrhosis
Liver Cirrhosis
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
The investigators aim to investigate the safety and efficacy of peripheral blood monocyte for the treatment of patients with advanced liver cirrhosis.
- Trial name
- NCT01503749
- Testing
- G-colony stimulating factor, Infusion of the mobilized monocyte cells
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Surgery, Obesity
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² > BMI ≥ 30 kg/m²) with…
- Conditions
- Surgery, Obesity, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NASHSURG (NCT03472157)
- Testing
- Lifestyle therapy, Bariatric surgery
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Decompensated Cirrhosis, Bleeding Varices
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced…
- Trial name
- NCT01370161
- Testing
- TIPS treatment, Medical treatment
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Air Force Military Medical University, China
Advanced Hepatocellular Carcinoma
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Primary Objectives: 1. To determine the maximum tolerated dose (MTD) or maximum recommended dose of SF1126 in combination with nivolumab in adult patients with advanced (unresectable or metastatic) HCC and Child-Pugh A or…
- Trial name
- NCT03059147
- Testing
- SF1126, Nivolumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- SignalRX Pharmaceuticals, Inc.
Liver Disease Chronic, Cirrhosis
cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit
The aim of this study is to conduct a quick assessment of potential liver damage caused by chronic alcohol consumption. Taking advantage of the patient's admission to a specialized detoxification unit, several tests will be…
- Conditions
- Liver Disease Chronic, Cirrhosis, Detoxification, Alcohol Abuse/Dependence
- Trial name
- HEP-UHD (NCT06838468)
- Testing
- Screening of compensated advance chronic liver disease
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Corporacion Parc Tauli
Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
Advanced liver disease and low ascitic fluid protein concentration have been identified as risk factors for spontaneous bacterial peritonitis in cirrhosis.
- Conditions
- Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome, Cirrhosis
- Trial name
- NCT00359853
- Testing
- Oral norfloxacin
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Hospital Clinic of Barcelona
Advanced Hepatocellular Carcinoma, Cirrhosis
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07042919
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Devalingam Mahalingam
Advanced Adult Hepatocellular Carcinoma
Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis.
- Trial name
- NCT04497038
- Testing
- Cabozantinib
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
HIV Infection, AIDS
HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation
An international investigation to evaluate if, and if so how long, autologous bone marrow hematopoietic stem cell transplantation can safely restore liver functions for HIV infected patients who have decompensated liver cirrhosis.
- Conditions
- HIV Infection, AIDS, Cirrhosis
- Trial name
- HIV-ABMi (NCT01309594)
- Testing
- Hematopoietic stem cell transplantation
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- National Center for Global Health and Medicine, Japan
Hepatocellular Carcinoma
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
- Trial name
- NCT02128958
- Testing
- CF102
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 78 people
- Sponsor
- Can-Fite BioPharma
Hepatitis C, Cirrhosis
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
- Conditions
- Hepatitis C, Cirrhosis, Fibrosis
- Trial name
- NCT00252642
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Liver Cirrhosis, Liver Fibrosis
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of GOV in Patients With cACLD
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing gastroesophageal…
- Conditions
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- Trial name
- NCT06144437
- Testing
- Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Psychiatric Disorder, Psychiatric Hospitalization
Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness.
- Conditions
- Psychiatric Disorder, Psychiatric Hospitalization, Advanced Chronic Liver Disease, Liver Fibrosis
- Trial name
- HEPSY (NCT05602870)
- Testing
- non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
- Where
- France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Cholangitis, Secondary Biliary, Cholangiocarcinoma
Advanced Endoscopy During COVID-19
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
- Conditions
- Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer
- Trial name
- NCT04385147
- Testing
- Endoscopic management according to standard of care
- Where
- 5 sites in United States, Egypt and 3 more
- Volunteers
- 670 people
- Sponsor
- Al-Azhar University
Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Magnetic Resonance Technics for the Assessment of Liver Function Before and After TIPS
Portal hypertension is the end-stage fatal complications of liver cirrhosis. Decompensated cirrhosis patients can pass through transjugular intrahepatic portosystemic shunt to effectively prevent bleeding and refractory ascites.
- Conditions
- Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Functional Magnetic Resonance Imaging
- Trial name
- NCT03933891
- Testing
- TIPS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- West China Hospital
Cirrhosis, Cirrhosis Advanced
Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis
To guide the administration of intravenous albumin by lung ultrasound in decompensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis Advanced, Acute Kidney Injury, Ascites
- Trial name
- POCUS (NCT07072572)
- Testing
- Lower albumin dosage
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Centro Medico Issemym
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Fibrosis Due to NASH
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants…
- Trial name
- NCT01672866
- Testing
- SIM
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 222 people
- Sponsor
- Gilead Sciences
Cirrhosis, Liver, Advanced Liver Fibrosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
- Trial name
- ECHO-B (NCT04172779)
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Diseases, Hepatitis C
GastrOesophageal Varices After Sustained Virological Response
Chronic hepatitis C remains a public health issue because up to 70 million people are chronically infected by hepatitis C virus (HCV) worldwide.
- Trial name
- GOVaSViR (NCT04191018)
- Testing
- Liver elastography, Splenic elastography, Gastrointestinal endoscopy
- Where
- 2 sites in Brazil
- Volunteers
- 322 people
- Sponsor
- Oswaldo Cruz Foundation